Starpharma Holdings Limited (SPHRF) Research

Starpharma Holdings Limited is a global biopharmaceutical firm dedicated to the investigation, advancement, and marketing of its proprietary dendrimer-based products for pharmaceutical, life science, and other diverse applications. Among its commercialized offerings is VivaGel, an antibiotic-free therapy designed for both preventing and managing bacterial vaginosis. The company's pipeline also features the VivaGel antiviral condom and VIRALEZE, an antiviral nasal spray. A cornerstone of Starpharma's innovation is its Dendrimer Enhanced Product (DEP) drug delivery platform. This advanced technology is being leveraged to develop a diverse portfolio of treatments, particularly in oncology. Several DEP-enhanced cancer therapies are currently progressing through clinical trials: DEP docetaxel, DEP cabazitaxel, and DEP irinotecan are all in Phase 2 studies, while DEP gemcitabine is undergoing Phase 1/2 trials. The DEP platform's utility extends further to radiotheranostics for cancer diagnosis and treatment, various Antibody Drug Conjugates (including DEP HER-2 ADC), and other non-oncology candidates. Additionally, DEP AZD0466 is advancing through Phase 1/2 clinical trials specifically for haematological malignancies. Starpharma Holdings Limited was established in 1996 and is headquartered in Abbotsford, Australia.

Open Starpharma Holdings Limited (SPHRF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.